Metrics as of 10/17/2026, 10:20 AM (Berlin time), refresh in progress.
Aurora Cannabis Inc.
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including…
1D
-2.7%
1W
-11.1%
1M
+4.2%
6M
+9.0%
YTD
-5.5%
1Y
-24.6%
2Y
-28.1%
5Y
-94.3%
10Y
-97.9%
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~24% stronger price swings than usual
PRICE TARGET LOW
US$1.00
CONSENSUS
US$5.92
MEDIAN
US$8.00
PRICE TARGET HIGH
US$8.75
0
STRONG BUY
3
BUY
8
HOLD
3
SELL
0
STRONG SELL
14
TOTAL · Hold
As of: 17/12/2020
P/E
-2.92
P/B
0.66
EV/EBITDA
-3.9
RETURN ON EQUITY
-0.8%
NET MARGIN
-6.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
97.2%
FLOAT SHARES
61,543,239
AVG. DAILY VOLUME (30D)
1,013,217
Aurora Cannabis Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is Miguel Martin, the company employs around 1,028 people.
The IPO was on 15/07/2014; the stock trades on NASDAQ under the ticker ACB.
14 analysts rate the stock, the consensus is Hold (as of 17/12/2020).
The average price target is US$5.92, ranging from US$1.00 to US$8.75, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 24% stronger than usual.
No, Aurora Cannabis currently does not pay a dividend.
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
Clicking "Analyze stock" lets five strategies assess Aurora Cannabis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.